Top Stories
While a combination of fianlimab plus Regeneron's PD-1 inhibitor Libtayo posted a numerically higher progression-free survival than Keytruda monotherapy, it did not achieve statistical significance.
Label expansions for Daiichi and AstraZeneca's HER2-targeting antibody-drug conjugate were based on the Phase III DESTINY-Breast11 and DESTINY-Breast05 trials.
The PD-L1 inhibitor is cleared for use in patients with muscle-invasive bladder cancer who have molecular residual disease following surgery.
The reported exit of Tracy Beth Høeg could come just days after the resignation of FDA Commissioner Marty Makary, according to Reuters.
Ligufalimab in combination with azacitidine and venetoclax achieved an objective response rate of 80%.
Conference News
More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12, ...
The long-term, pivotal, phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag achieving a statistically significant 55% reduction in risk of clinical worsening in predominantly pre-t...
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United StatesPositive Phase III readout of National Cancer Institute spons...
Re-induction with ADSTILADRIN resulted in complete responses in 31% of initial non-responders with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (n=13)Findings suggest...
PARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approac...
